After prioritizing liver disease asset, Boston Pharma sells FGF21 agonist to GSK for $1.2B up front

Once a diffuse organization with at least 15 assets in its pipeline, Boston Pharma made a liver disease program its top priority in recent years under the leadership of CEO Sophie Kornowski. Now, with the therapy ready for Phase III testing, GSK is acquiring the molecule for $1.2 billion up front.

GSK plc (LSE:GSK; NYSE:GSK) will gain efimosfermin alfa (BOS-580), an FGF21 agonist that Boston Pharmaceuticals Inc. believes has a dosing advantage over others in its class. The pharma is buying a subsidiary of the Gurnet Point Capital-backed biotech, which is eligible for a further $800 million in milestones beyond the upfront price...